Nanobiotix SA

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

18 9月 2024 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

04 9月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 9月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

08 8月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 7月 2024 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

12 6月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 6月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

02 6月 2024 10:00:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

28 5月 2024 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

23 5月 2024 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

22 5月 2024 02:00:00 条件 Nasdaq GlobeNewswire

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

21 5月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

16 5月 2024 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

15 5月 2024 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

14 5月 2024 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

24 4月 2024 16:40:39 条件 Nasdaq GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

17 4月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 4月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

02 4月 2024 16:15:00 条件 Nasdaq GlobeNewswire

Nanobiotix to Present at Upcoming Investor Conferences in March

06 3月 2024 16:15:00 条件 Nasdaq GlobeNewswire